[A20-41] Avelumab (renal cell carcinoma) - Addendum to Commission A19-95
Last updated 14.05.2020
Commission awarded on 06.04.2020 by the Federal Joint Committee (G-BA).
Treatment-naive adults with advanced renal cell carcinoma
Conclusion of dossier assessment A19-95 unchanged.
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
|A19-95||Avelumab (renal cell carcinoma) - Benefit assessment according to §35a Social Code Book V||Commission completed|
|G17-09||Avelumab (metastatic Merkel cell carcinoma) - Benefit assessment according to §35a (1), Sentence 11, Social Code Book V||Commission completed|